NanoVibronix, Inc. (NAOV)
Automate Your Wheel Strategy on NAOV
With Tiblio's Option Bot, you can configure your own wheel strategy including NAOV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAOV
- Rev/Share 5.541
- Book/Share 87.6331
- PB 0.0285
- Debt/Equity 0.0747
- CurrentRatio 0.8601
- ROIC -0.2058
- MktCap 1992288.0
- FreeCF/Share -15.0258
- PFCF -0.2736
- PE -0.3391
- Debt/Assets 0.0583
- DivYield 0
- ROE -0.1198
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes
Read More
ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
Published: December 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit Peak Medical, ENvue's Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit
Read More
NanoVibronix Announces Results from UroShield™ Case Series
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system. The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield.
Read More
About NanoVibronix, Inc. (NAOV)
- IPO Date 2015-05-28
- Website https://www.nanovibronix.com
- Industry Medical - Devices
- CEO Doron Robert Besser
- Employees 31